Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
estimated completion

Description

Summary

A Phase 1b/2, multicenter, open-label study designed to evaluate the efficacy and safety of ACP-196 in subjects with recurrent GBM who have progressed after 1 or 2 prior systemic treatment regimens.

Keywords

Glioblastoma Multiforme GBM Glioblastoma ACP-196

Eligibility

You can join if…

Open to people ages 18 years and up

  • Histologically confirmed GBM at first or second recurrence after concurrent or adjuvant chemotherapy or radiotherapy (must have received temozolomide).
  • Radiographic demonstration of disease progression by MRI following prior therapy.
  • ECOG performance status ≤ 2.
  • Life expectancy ≥ 12 weeks.
  • Completion of all prior anticancer therapy before first ACP-196 dose.

You CAN'T join if...

  • Three or more prior lines of systemic therapy for GBM.
  • Significant cardiovascular disease.
  • Evidence of bleeding diathesis or coagulopathy.
  • Requires urgent palliative intervention for primary disease.
  • History of stroke or clinically significant intracranial hemorrhage within 6 months before first dose of study drug.
  • Breastfeeding or pregnant.

Locations

  • UCLA Neurology-Oncology Program
    Los Angeles California 90095 United States
  • Stanford Cancer Center
    Palo Alto California 94305 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Acerta Pharma BV
ID
NCT02586857
Phase
Phase 1/2
Study Type
Interventional
Last Updated